In January 2025, China’s innovative pharmaceutical sector continues to make its mark on the global stage. The collaboration between Innovent Biologics and Roche marks the international launch of IBI3009, an antibody-drug conjugate (ADC) targeting small cell lung cancer (SCLC). Meanwhile, the partnership between Duality Biologics and Avenzo Therapeutics concerning the EGFR/HER3 bispecific ADC, DB-1418/AVZO-1418, further demonstrates China’s progress in developing complex and efficient cancer ther

Feb. 18, 2025 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) to be presented at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 27 – March 1, 2025, in West Palm Beach, Florida. Abstracts are n

$3.7 Million Private Placement Financing from Existing Investors $2.0 Million Funding Advance from the Cancer Prevention and Research Institute of Texas (CPRIT) Feb. 18, 2025 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company,” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced today that it has closed a private placement with aggregate initial upfront p

Feb. 18, 2025 -- Bionic Sight, Inc., a company developing a novel gene therapy for retinal degenerative diseases, announced today that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational product BS01 for the treatment of retinitis pigmentosa (RP) patients with advanced stage vision loss. RMAT designation is part of the 21st Century Cures Act, which aims to accelerate the development of regenerative medicine therapies, including gene therapy, for se

Feb. 18, 2025 -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), a biologic used to treat eye disorder

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision expected by June 20, 2025 Priority review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by in

Through comprehensive searches in the Patsnap Synapse database, it has been found that the key drugs targeting ActRII mainly consist of fusion proteins and monoclonal antibodies. These drugs have shown significant potential in the treatment of various diseases, and understanding their characteristics and development progress is crucial for evaluating their clinical value and future research directions. When searching for “ActRII” under the “Target” section within the “Drug Finder” tool in Patsn

In January 2025, several significant mergers and acquisitions (M&A) took place in the biopharmaceutical industry. These transactions not only reflect the strategic positioning of major companies in specific therapeutic areas but also demonstrate the industry's continued focus on innovative technologies and unmet medical needs. Lantheus Holdings, a leader in the field of radiopharmaceuticals, has significantly strengthened its market position and technological portfolio through a series of ac

Feb. 16, 2025 - The Bahrain Oncology Centre (BOC) has made medical history by successfully treating a sickle cell disease (SCD) patient using CRISPR-based gene-editing therapy, Casgevy (exagamglogene autotemcel). This marks the first successful treatment of its kind outside the United States, positioning Bahrain as a global leader in precision medicine and innovative healthcare solutions. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the first licensed therapy to uti

Feb. 11, 2025 -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, marks its 10-year anniversary this month, a milestone that demonstrates the company’s long-term commitment to unlock the power of precision diagnostics, transform healthcare, and end the diagnostic odyssey for patients with the most complex genetic disorders. Established in 2015 as a joint venture with Baylor College of Medicine, the #1 NIH-funded Department of Molecular and Human Genetics i